Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: Jon Koplik who wrote (2304)	3/16/2000 11:38:00 AM
From: Ilaine	Read Replies (1) \| Respond to of 3576

I just don't see how United States patent law allows researchers to patent naturally-occurring gene sequences. 35 U.S.C. 102 requires the thing to be patented, here the gene sequence, to be novel - so a genetically-engineered or altered gene can be patented because it is novel, but something which is naturally occurring isn't novel. You can't patent air or sunshine or water. How can you patent something that every human has in their DNA? The relevant definition from 35 U.S.C.A. õ 103(b) (West Supp. 1997). (3) For purposes of paragraph (1), the term "biotechnological process" means- (A) a process of genetically altering or otherwise inducing a single- or multi-celled organism to- (i) express an exogenous nucleotide sequence, (ii) inhibit, eliminate, augment, or alter expression of an endogenous nucleotide sequence, or (iii) express a specific physiological characteristic not naturally associated with said organism; (B) cell fusion procedures yielding a cell line that expresses a specific protein, such as a monoclonal antibody; and (C) a method of using a product produced by a process defined by subparagraph (A) or (B), or a combination of subparagraphs (A) and (B).